Transcatheter aortic valve implantation in 2015

作     者：Darren Mylotte Faisal Sharif Nicolo Piazza Marco Moscarelli Khalil Fattouch Thomas Modine 

作者机构：University Hospital Galway Ireland McGill University Health Centre Montreal Quebec Canada GVM Care and Research Unit Anthea Hospital Bari ltaly GVM Care and Research Unit Maria Eleonora Hospital Palermo Italy Hopital Cardiologique Lille France 

出 版 物：《Journal of Geriatric Cardiology》 (老年心脏病学杂志（英文版）)

年 卷 期：2016年第13卷第6期

页      面：511-513页

核心收录：

学科分类：0832[工学-食品科学与工程（可授工学、农学学位）] 0905[农学-畜牧学] 08[工学] 09[农学] 090501[农学-动物遗传育种与繁殖] 083201[工学-食品科学] 

主　　题：Aortic valve Echocardiography Risk factor Surgery 

摘      要：The last decade has seen transcatheter aortic valve implantation （TAVI） emerge as the standard of care for patients with severe symptomatic aortic stenosis deemed to be either at excessiveor high-risk for surgical aortic valve replacement （SAVR）. This position is supported by three important multicentre randomized trials comparing TAVI to the historical gold standard therapies： （1） The Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve （PARTNER） IB Trial compared TAVI （Edwards SAPIEN, Edwards Lifesciences Inc., Irvine, CA） to optimal medical therapy in patients at excessive surgical risk, and demonstrated an absolute mortality reduction of 〉 20% at 1-year, an effect that was maintained out to 5-year follow-up;Ill （2） The PARTNER 1A Trial compared TAVI （Edwards SAPIEN, Edwards Lifesciences Inc.,